Management of Brain Metastasis in Patients with Metastatic Prostate Cancer
Berin Gulatar Turkoglu (Author), Kadriye Agan Yildirim (Author)
Release Date: 2024-06-19
In this section, where the concepts of family and marriage are defined, the importance and history of these concepts, the perspectives of Turkey and other countries on marriage and family, the structural features of the family and its place in society, the functions of the family, and family types are explained in detail. When the [...]
Media Type
Buy from
Price may vary by retailers
Work Type | Book Chapter |
---|---|
Published in | Current Management of Metastatic Prostate Cancer |
First Page | 185 |
Last Page | 194 |
DOI | https://doi.org/10.69860/nobel.9786053359142.18 |
Page Count | 10 |
Copyright Holder | Nobel Tıp Kitabevleri |
License | https://nobelpub.com/publish-with-us/copyright-and-licensing |
Family is a social structure in which we feel the happiness of belonging, feel safe in every aspect, and learn about life and living together with others. Basic life needs are met within the family, and the longest interaction occurs here. The basic behaviours and life habits that form personality are acquired through this interaction. Family constitutes the first and most important dimension of an individual’s social environment. The child’s upbringing as an individual in accordance with society’s expectations is achieved within the family.
In marriages, it is essential for the art of being happy that both men and women have their own spaces and areas to be together.
Berin Gulatar Turkoglu (Author)
MD, Assistant Professor, Marmara University
https://orcid.org/0000-0003-0791-4377
3Berin Gulatar-Turkoglu is an Assistant Professor of Neurology at the Marmara University Faculty of Medicine and is also European Board of Neurology certified. Dr. Gulatar-Turkoglu has a deep interest in the topics Clinical Electroneurophysiology and Headache and continues to contribute to the literature in these fields. She is currently a delegate of Turkish Medical Association.
Kadriye Agan Yildirim (Author)
MD, Professor of Neurology, Marmara University
https://orcid.org/0000-0001-5696-6435
3Kadriye Agan-Yildirim has built a distinguished career in the field of Clinical Electroneurophysiology and is currently a Professor of Neurology at the Marmara University Faculty of Medicine. Her work has led to the publication of over 100 research articles, oral and poster presentations, and reviews. She contributed to the literature with valuable peer-reviewed papers principally focused on the epilepsy and sleep disorders but also on the topics such as multiple sclerosis and ataxias. Kadriye Agan-Yildirim has also been involved in numerous research projects throughout her career.
Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, et al. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. Prostate. 2014;74(2):210-6.
Marchand Crety C, Ettalhaoui L, Servagi Vernat S. Cystic brain metastasis from prostate cancer: A case report and literature review. Urol Case Rep. 2020;32:101219.
Caffo O, Veccia A, Fellin G, Mussari S, Russo L, Tomio L, et al. Frequency of brain metastases from prostate cancer: an 18-year single-institution experience. J Neurooncol. 2013;111(2):163-7.
Tremont-Lukats IW, Bobustuc G, Lagos GK, Lolas K, Kyritsis AP, Puduvalli VK. Brain metastasis from prostate carcinoma: The M. D. Anderson Cancer Center experience. Cancer. 2003;98(2):363-8.
Bhambhvani HP, Greenberg DR, Srinivas S, Hayden Gephart M. Prostate Cancer Brain Metastases: A Single-Institution Experience. World Neurosurg. 2020;138:e445-e9.
Hatzoglou V, Patel GV, Morris MJ, Curtis K, Zhang Z, Shi W, et al. Brain metastases from prostate cancer: an 11-year analysis in the MRI era with emphasis on imaging characteristics, incidence, and prognosis. J Neuroimaging. 2014;24(2):161-6.
Takei H, Rouah E, Ishida Y. Brain metastasis: clinical characteristics, pathological findings and molecular subtyping for therapeutic implications. Brain Tumor Pathol. 2016;33(1):1-12.
Kumthekar P, Le Rhun E. Brain Metastases and Leptomeningeal Disease. Continuum (Minneap Minn). 2023;29(6):1727-51.
Hutton R, Maguire J, Amer T, Fitzpatrick J, Hasan R, Ablett M, et al. Intracranial metastasis of adenocarcinoma of the prostate presenting with symptoms of spinal cord compression. Indian J Surg. 2015;77(Suppl 1):75-6.
Taddei G, Marzi S, Coletti G, De Paulis D, Ricci A, Galzio RJ. Brain Metastasis From Prostate Adenocarcinoma: Case Report and Review of Literature. World J Oncol. 2012;3(2):83-6.
Salvati M, Frati A, Russo N, Brogna C, Piccirilli M, D’Andrea G, et al. Brain metastasis from prostate cancer. Report of 13 cases and critical analysis of the literature. J Exp Clin Cancer Res. 2005;24(2):203-7.
Mahmoud AM, Childs DS, Ahmed ME, Tuba Kendi A, Johnson GB, Orme JJ, et al. Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis. Prostate. 2024;84(3):237-44.
Mirmoeeni S, Azari Jafari A, Shah M, Salemi F, Hashemi SZ, Seifi A. The Clinical, Diagnostic, Therapeutic, and Prognostic Characteristics of Brain Metastases in Prostate Cancer: A Systematic Review. Prostate Cancer. 2022;2022:5324600.
Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, et al. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med. 2012;37(7):637-43.
Niaz MJ, Sun M, Skafida M, Niaz MO, Ivanidze J, Osborne JR, et al. Review of commonly used prostate specific PET tracers used in prostate cancer imaging in current clinical practice. Clin Imaging. 2021;79:278-88.
Rajeswaran K, Muzio K, Briones J, Lim-Fat MJ, Tseng CL, Smoragiewicz M, et al. Prostate Cancer Brain Metastasis: Review of a Rare Complication with Limited Treatment Options and Poor Prognosis. J Clin Med. 2022;11(14).
Myint ZW, Qasrawi AH. Prostate Adenocarcinoma with Brain Metastasis: A Surveillance, Epidemiology, and End Results Database Analysis 2010-2015. Med Sci Monit. 2021;27:e930064.
Vrignaud P, Semiond D, Benning V, Beys E, Bouchard H, Gupta S. Preclinical profile of cabazitaxel. Drug Des Devel Ther. 2014;8:1851-67.
Al-Salama ZT. Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer. Drugs. 2019;79(14):1591-8.
Scott LJ. Enzalutamide: A Review in Castration-Resistant Prostate Cancer. Drugs. 2018;78(18):1913-24.
Benoist GE, Hendriks RJ, Mulders PF, Gerritsen WR, Somford DM, Schalken JA, et al. Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide. Clin Pharmacokinet. 2016;55(11):1369-80.
Lawlor D, Martin P, Busschots S, Thery J, O’Leary JJ, Hennessy BT, et al. PARP Inhibitors as P-glyoprotein Substrates. J Pharm Sci. 2014;103(6):1913-20.
Sun K, Mikule K, Wang Z, Poon G, Vaidyanathan A, Smith G, et al. A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models. Oncotarget. 2018;9(98):37080-96.
Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213- 23.
Soffietti R, Abacioglu U, Baumert B, Combs SE, Kinhult S, Kros JM, et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro Oncol. 2017;19(2):162-74.
Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665-72.
Yamamoto M, Serizawa T, Higuchi Y, Sato Y, Kawagishi J, Yamanaka K, et al. A Multi-institutional Prospective Observational Study of Stereotactic Radiosurgery for Patients With Multiple Brain Metastases (JLGK0901 Study Update): Irradiation-related Complications and Long-term Maintenance of Mini-Mental State Examination Scores. Int J Radiat Oncol Biol Phys. 2017;99(1):31-40.
Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1049-60.
Hong AM, Fogarty GB, Dolven-Jacobsen K, Burmeister BH, Lo SN, Haydu LE, et al. Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. J Clin Oncol. 2019;37(33):3132-41.
Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29(2):134-41.
Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013;15(10):1429- 37.
Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS, et al. Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. J Clin Oncol. 2020;38(10):1019-29.
Alamiri J, Britton CJ, Ahmed ME, Andrews JR, Higa JL, Dundar A, et al. Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis. Prostate. 2022;82(16):1483-90.
Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncology. 2020;6(5):650-9.
Decaestecker K, De Meerleer G, Ameye F, Fonteyne V, Lambert B, Joniau S, et al. Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. BMC Cancer. 2014;14:671.
Bianchi L, Ceci F, Balestrazzi E, Costa F, Droghetti M, Piazza P, et al. PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment. Cancers (Basel). 2023;15(7).
Pikis S, Bunevicius A, Lee CC, Yang HC, Zacharia BE, Liščák R, et al. Stereotactic radiosurgery for prostate cancer cerebral metastases: an international multicenter study. J Neurosurg. 2022;136(5):1307-13.
Kim SH, Chao ST, Toms SA, Vogelbaum MA, Barnett GH, Suh JH, et al. Stereotactic radiosurgical treatment of parenchymal brain metastases from prostate adenocarcinoma. Surg Neurol. 2008;69(6):641-6; discussion 6.
Flannery T, Kano H, Niranjan A, Monaco EA, 3rd, Flickinger JC, Lunsford LD, et al. Stereotactic radiosurgery as a therapeutic strategy for intracranial metastatic prostate carcinoma. J Neurooncol. 2010;96(3):369-74.
Walbert T, Harrison RA, Schiff D, Avila EK, Chen M, Kandula P, et al. SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol. 2021;23(11):1835-44.
Boxley PJ, Smith DE, Gao D, Kessler ER, Echalier B, Bernard B, et al. Prostate Cancer Central Nervous System Metastasis in a Contemporary Cohort. Clin Genitourin Cancer. 2021;19(3):217-22.e1.
onix_3.0::thoth | Thoth ONIX 3.0 |
---|---|
onix_3.0::project_muse | Project MUSE ONIX 3.0 |
onix_3.0::oapen | OAPEN ONIX 3.0 |
onix_3.0::jstor | JSTOR ONIX 3.0 |
onix_3.0::google_books | Google Books ONIX 3.0 |
onix_3.0::overdrive | OverDrive ONIX 3.0 |
onix_2.1::ebsco_host | EBSCO Host ONIX 2.1 |
csv::thoth | Thoth CSV |
json::thoth | Thoth JSON |
kbart::oclc | OCLC KBART |
bibtex::thoth | Thoth BibTeX |
doideposit::crossref | CrossRef DOI deposit |
onix_2.1::proquest_ebrary | ProQuest Ebrary ONIX 2.1 |
marc21record::thoth | Thoth MARC 21 Record |
marc21markup::thoth | Thoth MARC 21 Markup |
marc21xml::thoth | Thoth MARC 21 XML |